Dermapharm Holding SE
XETRA:DMP
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
30.15
42.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Dermapharm Holding SE
Dermapharm Holding SE
Cash & Cash Equivalents
Dermapharm Holding SE
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash & Cash Equivalents
€118.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash & Cash Equivalents
$45m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Cash & Cash Equivalents
€4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
11%
|
|
|
Merck KGaA
XETRA:MRK
|
Cash & Cash Equivalents
€3.2B
|
CAGR 3-Years
28%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
9%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Cash & Cash Equivalents
€4.6m
|
CAGR 3-Years
131%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Cash & Cash Equivalents
€40.8m
|
CAGR 3-Years
72%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
Dermapharm Holding SE
Glance View
In the bustling world of pharmaceuticals, Dermapharm Holding SE stands as a noteworthy player, crafting a narrative of strategic growth and innovation. Founded in 1991 and headquartered in Grünwald, Germany, Dermapharm presents itself as a vertically integrated pharmaceutical company whose operations stretch from development and production to marketing and distribution. This integration allows them to maintain control over their value chain, ensuring efficiency and quality across diverse product lines. Dermapharm's portfolio spans over 900 active pharmaceutical ingredients, health products, and medical devices, fortified through keenly orchestrated acquisitions that enhance their market presence and product offerings. Such strategic steps enable Dermapharm to leverage established brands while venturing into new sectors, reinforcing its reputation as a dynamic force in the pharmaceutical landscape. Dermapharm primarily generates revenue by capitalizing on dermatological products, allergy treatments, systemic corticosteroids, and vitamin supplements. By addressing a broad spectrum of chronic and everyday health conditions, they serve both niche and mass-market demands across Europe. Dermapharm’s distinctive approach combines robust in-house research and development with targeted acquisitions, such as their acquisition of the Dr. Loges-Schuten pharmaceutical company, broadening their reach into phyto-pharmaceuticals and other sectors. Additionally, Dermapharm collaborates with partners to penetrate new geographical markets, thereby diversifying their revenue streams. Such initiatives underscore the company's agility and strategic foresight, ensuring sustained growth in a competitive industry.
See Also
What is Dermapharm Holding SE's Cash & Cash Equivalents?
Cash & Cash Equivalents
118.6m
EUR
Based on the financial report for Sep 30, 2024, Dermapharm Holding SE's Cash & Cash Equivalents amounts to 118.6m EUR.
What is Dermapharm Holding SE's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
12%
Over the last year, the Cash & Cash Equivalents growth was 1%.
You don't have any saved screeners yet
